Truist cuts Perspective Therapeutics stock price target on timeline
Truist Securities reduced its price target for Perspective Therapeutics (NYSE: CATX) to $8.00 from $11.00, citing clinical trial timelines. The stock is down 77% in six months. Other analysts have mixed views, with targets ranging from $4.00 to $14.00. The company has cash runway into 2028 but is burning cash quickly.
How this was made
The 30-second read
Why it matters
The Truist target cut adds to a series of downward revisions, increasing short‑term downside risk.
Market read
Analyst target revisions are a key driver for micro‑cap biotech price moves; this cut may trigger further selling.
What to watch
Potential upside if Phase‑2 data exceeds expectations or if new partnership announcements occur.
Background
Perspective Therapeutics is a clinical‑stage biotech developing radiopharmaceuticals. Recent analyst coverage has been mixed, with price targets ranging from $4 to $14.
Ticker impact
Truist Securities lowered its price target on Perspective Therapeutics (CATX) to $8.00 from $11.00 after the company reported Q3 2026 earnings and trial enrollment updates.
likely pressure as the market prices in the lower target and cash‑burn concerns
The target reduction reflects concerns over cash runway and trial timelines, which typically weigh on a micro‑cap biotech's share price.
Market effects
May dampen sentiment toward small‑cap biotech stocks awaiting trial data.
Limited to U.S. biotech investors.
Low, as the company is micro‑cap and primarily U.S. focused.
Counterpoint
Some investors may view the lower target as an entry point if they believe trial data will improve.
Key entities
- analystTruist Securities
Equity research firm that lowered the price target.
- companyPerspective Therapeutics
Biotech firm (ticker CATX) subject of the coverage.
